Here are five details:
1. Per the agreement, Imris will exclusively use and sell Siemens’ MRI, computed tomography and angiography devices.
2. Although Imris will only use Siemens technology to build an Imris Surgical Theater, the company will continue to use equipment and devices from various manufacturers.
3. The Imris Surgical Theater is designed to allow neurosurgeons to conduct imaging without transferring the patient out of the operating room. The neurosurgeon can then alter the surgical pathway while the procedure is in progress.
4. The surgical theater costs between $1.5 million and $10 million. Neurosurgeons have reported a 30-point increase in the percentage of patients with tumors completely removed when intraoperative imaging is used
5. When asked the possibility of a Siemens acquisition, Imris’ CEO Andrew Flanagan indicated the company is working on internal tasks to boost research and development rather than finding a buyer.
More articles on devices and implants:
Trice Medical launches 1st dynamic imaging platform: 3 notes
OrthoSensor reaches milestone with 50,000 sensors distributed globally: 3 insights
Global spinal fusion devices market to exceed $10B by 2025: 5 market details
